



# Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort

Sylvia Binck<sup>1,2\*</sup>, Claire Pauly<sup>1,2</sup>, Michel Vaillant<sup>3</sup>, Geraldine Hipp<sup>1</sup>, Manon Gantenbein<sup>3</sup>, Rejko Krueger<sup>1,2,3</sup> and Nico J Diederich<sup>2</sup>

<sup>1</sup> Luxembourg Centre for System Biomedicine, University of Luxembourg, Luxembourg, Luxembourg, <sup>2</sup> Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg, <sup>3</sup> Luxembourg Institute of Health, Luxembourg, Luxembourg

## OPEN ACCESS

### Edited by:

Davide Martino,  
University of Calgary, Canada

### Reviewed by:

Shakya Bhattacharjee,  
Plymouth Hospitals NHS Trust,  
United Kingdom  
Matteo Bologna,  
Sapienza University of Rome, Italy

### \*Correspondence:

Sylvia Binck  
binck.sylvia@chl.lu

### Specialty section:

This article was submitted to  
Movement Disorders,  
a section of the journal  
Frontiers in Neurology

**Received:** 01 July 2020

**Accepted:** 09 October 2020

**Published:** 12 November 2020

### Citation:

Binck S, Pauly C, Vaillant M, Hipp G, Gantenbein M, Krueger R and Diederich NJ (2020) Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort. *Front. Neurol.* 11:578924. doi: 10.3389/fneur.2020.578924

**Background:** To establish the frequency of impulse control disorder (ICD) in Parkinson's disease (PD).

**Methods:** Within the Luxembourg Parkinson's Study, PD patients were evaluated for ICD presence (score  $\geq 1$  on MDS-UPDRS I item 1.6), use of dopamine agonists (DA) and other medications.

**Results:** 470 patients were enrolled. Among 217 patients without DA use, 6.9% scored positive for ICD, vs. 15.4% among 253 patients with DA use ( $p = 0.005$ ). The regression analysis showed that age at PD diagnosis had only a minor impact on ICD occurrence, while there was no influence by gender or co-medications. The longitudinal study over 2 years in 156 patients demonstrated increasing ICD frequency in DA users ( $p = 0.005$ ).

**Conclusion:** This large and non-interventional study confirms that PD patients with DA treatment show higher frequency of ICD than patients without DA use. It newly demonstrates that ICD can develop independently from age, gender, or co-medications.

**Keywords:** impulse control disorder, dopamine agonists, Parkinson's disease (PD), risk factors, longitudinal analysis

## INTRODUCTION

Impulse control disorder (ICD) has been described by the World Health Organization (WHO) in 1992 as "repeated acts that have no clear rational motivation, generally harm the person's own interests and those of other people, and are associated with impulses the person experiences as uncontrollable" (1).

Following the WHO definition, four types of ICD have been defined: binge eating, excessive shopping, pathological gambling and hypersexuality (2, 3). Pilot studies on ICD in PD have also proposed to classify hobbyism and sometimes punning under the ICD umbrella (4, 5). Although the latter behaviors may also reflect perturbed impulse-control, they are less strictly defined and are frequently overlapping with normal behavior (6).

The dopamine dysregulation syndrome characterized by excessive and addictive use of dopaminergic medication can be more easily dissected, as in contrast to ICD, it overwhelmingly is due to excessive use of levodopa and not dopamine agonists (6, 7).

The frequency of ICD in *de novo* PD patients is similar to the general population (5), but numerous studies reported higher frequency during the course of the disease (8–12). Treatment by dopamine agonists (DA), mainly through stimulation of the D3- receptor (13) has been proposed as a causal factor.

However, there is ongoing debate on other risk factors, as not every PD patient treated by DA develops ICD. Previous studies essentially recruited younger PD patients or those with a more rapid disease progression in tertiary care centers (5, 9, 11). Therefore, these studies cannot extrapolate their findings to the general PD population. Potential further risk factors such as age at PD diagnosis, gender, genetic susceptibility factors, comorbidities, or co-medication have been poorly addressed (14). Whether the dopamine agonist specifically or the dopamine replacement therapy in general, reflected by the levodopa equivalent daily dose (LEDD), is implicated in the development of ICD, is also subject of discussion. Finally, the development of ICD in PD over time has only been explored in a few longitudinal studies (5, 9, 11).

The present study could successfully circumvent some of these reservations. The Luxembourg Parkinson's study (15) was designed to be as inclusive as possible by active recruitment of also elderly participants or those with reduced mobility, thus best representative of the general PD population (16). This allows our study to produce statistically robust data on most of these so far debatable issues.

## METHODS

### Cohorts of PD Patients and Controls

PD patients were recruited from the Luxembourg Parkinson's study (15). In this descriptive, longitudinal, prospective study, participants benefit from detailed annual follow-up examinations." Subjects were eligible for the study when fulfilling the following criteria: PD diagnosis based on the UK PD Society Brain Bank criteria (17) and a score of  $\geq 18$  points on the Montreal Cognitive Assessment (MoCA) (18) in order to ensure sufficient comprehension of the questionnaires used. Patients with atypical PD were excluded. Based on DA treatment, patients were divided in two groups: "DA-users" (DA+) and "non DA-users" (DA-). They were adjusted for age and gender. Controls were also recruited from the Luxembourg Parkinson's study (15). They only had a baseline assessment and were adjusted for age at study entry with patients classified as DA-. We excluded controls with any suspicion of incident PD or under DA treatment for other medical reasons. For the longitudinal analysis in PD patients, we only considered those who did not secondarily convert into atypical Parkinsonism.

### Assessments

For each enrolled subject we assessed the demographic data and the current medication, including levodopa, DA, amantadine and antidepressants. Based on the indicated dosages of all dopaminergic agents, a levodopa equivalent daily dose was calculated (LEDD) (19). Previous dosages of the present medication were not assessed. We evaluated the MDS-UPDRS part I-IV (20) and the modified Hoehn and Yahr scale (21).

Similarly to another study on ICD occurrence in PD (5), ICD was evaluated by assessing MDS-UPDRS part I item 1.6. This

item quantifies ICD with a score ranging from zero (normal) to four (severe). We defined the presence of ICD by a score  $\geq 1$ , as previously proposed (5).

Of note, the proposed text of the MDS-UPDRS part I item 1.6 was explained in detail to the patient, with the examiner insisting on the five above-mentioned symptoms of ICD. Any allusion to punning as well as excessive and addictive intake of the dopaminergic medication were disregarded.

### Statistical Analyses

The study data were managed by using the Redcap electronic data capture tools (22). The statistical analyses were performed using SPSS Statistics version 25 and SAS V9.3 (SAS Institute, Cary, NC, USA). All tests were two-sided and  $p \leq 0.05$  were considered statistically significant. Assumption of normality was tested by the Shapiro-Wilk test. ICD frequency was calculated by a chi square test and demographic variables also by the Mann-Whitney U-test as adequate. We performed a logistic regression model to estimate the relationship between ICD presence and confounding factors by putting them all into one model. In a second analysis, interactions between DA use and the annual visits V1 and V3 were tested. In both models, adjustments on gender and age were implemented.

All patients had given written consent before entering the Luxembourg Parkinson's study (15). The study was approved by the National Ethics Board (CNER Ref: 201407/13) and the National Data Protection Committee (CNPD Ref: 446/2017).

## RESULTS

### Baseline Characteristics

Between March 2015 and December 2019, 470 patients (mean age 66.4 [39.4–86.4] years) and 429 controls (mean age 66.8 [55.2–89.5] years) were eligible for the study. Two hundred and fifty three patients (54%) were classified DA+ and 217 DA- (mean age 66.6 [51–86] vs. 66.9 years [39–80],  $p = 0.2$ ). DA+ were younger at PD diagnosis than DA- (58.5 [27.2–78.4] vs. 61.2 [31.3–79.4] years;  $p = 0.001$ ) and had a longer disease duration (8.1 [0–34] vs. 5.7 [0–26] years,  $p < 0.001$ ). The complete comparison of the demographic data is shown in **Table 1**.

### ICD Frequencies

Based on the answers to the assessment, ICD frequency was higher in PD patients than in controls (11.5 % vs. 4.6%;  $p < 0.001$ ). This difference was probably due to a higher positive scoring in DA+ (39 out of 253 DA+ [15.4%] vs. 15 out of 217 DA- [6.9%],  $p = 0.005$ ).

Fifty four patients in total scored positive for ICD (38 males and 16 females). The most common ICD subtype in men was binge eating and in women excessive shopping. The detailed data about ICD subtypes and male-female distribution can be found in **Table 2**.

Twenty one Patients with advanced treatment (19 with Deep brain stimulation, two with apomorphine or Duodopa-pump) were included. Three patients with DBS scored positive for ICD. There was no statistically significant association between DBS treatment and ICD symptoms ( $p = 0.55$ ).

**Abbreviations:** DA, dopamine agonist; DA+, DA-users; DA-, non DA-users; ICD, impulse control disorder; LEDD, levodopa equivalent daily dosage; MDS-UPDRS, Movement Disorder Society Unified Parkinson's Disease Rating Scale; PD, Parkinson's disease; V1, Visit 1; V3, Visit 3.

**TABLE 1** | Demographics and medication profile in 470 patients (253 DA+, 217 DA-) and 429 controls.

	All PD patients	PD DA+	PD DA-	<i>p</i> -value DA+ vs. DA-	Controls	<i>p</i> -value PD DA- vs. controls
Subjects	470	253	217		429	
<b>Demographics</b>						
Male sex (%)	308 (65.5%)	156 (61.7%)	152 (70.0%)	0.06	234 (54.5%)	<0.001**
Years of education (yrs.)	13.0 (±3.9)	13.1 (±3.6)	12.9 (±4.3)	0.70	13.8 (3.7)	0.01*
MoCA	25.2 (±3.1)	25.4 (±3.0)	24.9 (±3.2)	0.11	26.9 (2.5)	<0.001**
Age at baseline (yrs.)	66.8 (±8.5)	66.6 (±8.0)	66.9 (±9.0)	0.18	66.8 (8.5)	0.35
Age at PD onset (yrs.)	59.8 (±9.9)	58.5 (±9.3)	61.2 (±10.4)	0.001**	n.a	n.a
PD duration (yrs.)	6.9 (±5.5)	8.0 (±5.5)	5.7 (±5.2)	<0.001**	n.a	n.a
LEDD (mg)	559 (±441)	696 (±429)	397 (±399)	<0.001**	0	n.a
<b>Scores</b>						
MDS-UPDRS I 1.6 = 0 ( <i>n</i> )	416 (88.5%)	214 (84.6%)	202 (93.1%)	n.a	409 (95.4%)	n.a
MDS-UPDRS I 1.6 ≥ 1 ( <i>n</i> )	54 (11.5%)	39 (15.4%)	15 (6.9%)	n.a	20 (4.6%)	n.a
MDS-UPDRS III (score)	33.2 (±14.4)	33.2 (±15.3)	33.2 (±13.3)	0.8	3.7 (4.0)	n.a
Hoehn & Yahr (score)	2.1 (±0.9)	2.2 (±0.7)	2.1 (±0.6)	0.61	0	n.a
<b>Medication</b>						
Amantadine ( <i>n</i> )	81 (17.2%)	48 (19.0%)	33 (15.2%)	n.a	n.a	n.a
Antidepressants ( <i>n</i> )	64 (13.9%)	34 (13.2%)	30 (14.4%)	n.a	20 (4.6%)	n.a
Ropinirole ( <i>n</i> )	63 (13.4%)	63 (26.8%)	0	n.a	0	n.a
Pramipexole ( <i>n</i> )	146 (31.1%)	146 (62.2%)	0	n.a	0	n.a
Rotigotine ( <i>n</i> )	32 (6.8%)	32 (13.6%)	0	n.a	0	n.a
Apomorphine ( <i>n</i> )	1 (0.6%)	1 (1.2%)	0	n.a	0	n.a
Piribedil ( <i>n</i> )	16 (3.4%)	16 (6.8%)	0	n.a	0	n.a

*p*-values concern differences between DA+ and DA- (\**p* < 0.05, \*\**p* < 0.01). Some patients take >1 DA, which explains >100% in the DA+.

**TABLE 2** | ICD subtypes with male-female distribution in subjects with MDS-UPDRS ≥ 1 at baseline (54 patients).

	Male ( <i>n</i> = 30)	Female ( <i>n</i> = 10)	<i>p</i> -value
Binge eating ( <i>n</i> )	12	2	<i>p</i> = 0.14
Excessive shopping ( <i>n</i> )	7	4	<i>p</i> = 0.58
Pathological gambling ( <i>n</i> )	0	2	<i>p</i> = 0.03*
Hypersexuality ( <i>n</i> )	6	0	<i>p</i> = 0.09
Hobbying ( <i>n</i> )	5	2	<i>p</i> = 0.95
Total ( <i>n</i> )	30	10	

\**p* ≤ 0.05 is considered statistically significant.

Notably, there was no significant difference in ICD frequency between DA- patients and controls (6.9% vs. 4.6%, *p* = 0.21).


## Potential ICD Risk Factors

We analyzed the potential influence of ICD risk factors by a logistic regression model (**Supplementary Table 1**). We found that younger age at disease onset independently affected ICD occurrence (*p* = 0.03). We also found that the higher the age of onset, the higher the ICD frequency. The odds ratio was borderline significant (OR = 1.003, 95%CI = [1.000; 1.006]). There was no influence of gender (*p* = 0.1), disease duration (*p* = 0.2), UPDRS III (*p* = 0.06), use of amantadine (*p* = 0.5)

or antidepressants (*p* = 0.5). Despite the fact that LEDD was higher in DA+ than in DA- (696 [0–1625] vs. 397 mg [0–2112], *p* < 0.001) our model did not show an association (*p* = 0.2). In a next step, we adjusted both patient subgroups for age at PD diagnosis: 242 DA+ and 203 DA-. The difference in ICD frequency was maintained (14.9% vs. 7.4, *p* = 0.02). In a final step, we separately analyzed ICD occurrence in 285 PD patients older than 65 years at study entry: 145 DA+ and 140 DA- patients. Here, the difference was also maintained (12.5% vs. 4.3%, *p* = 0.01).

## Longitudinal Follow-Up of ICD

The database identified 193 patients having accomplished visits V1 to V3. Three patients were excluded because of conversion into atypical parkinsonism during follow-up (one patient was reclassified as Lewy Body Dementia and two as secondary parkinsonism). We based our analysis on the 156 patients with unchanged DA group adherence from baseline to V3: 102 PD patients in the DA+ subgroup and 54 patients in the DA-subgroup. There was a sharp increase from baseline to V3 in the DA+ subgroup (7.9% vs. 26.5%, *p* < 0.001). In contrast, ICD frequency remained stable in the DA- group (5.6%). When comparing ICD occurrence between both groups at V3, the difference was again significant (26.5% vs. 5.6%, *p* < 0.001) (**Figure 1**). Of note, we did have participants with a longer follow-up period (up to 4 years). However, statistical robustness of



a longitudinal model was not achieved because of insufficient subjects and these data are not shown.

## DISCUSSION

This study confirms a higher ICD frequency in DA+ than in DA- PD patients. As frequency in DA- is similar to the frequency in age-adjusted controls, ICD is not a PD-inherent syndrome. Age at PD onset is a significant co-factor, but age at study entry is not. Remarkably, ICD frequency remains significantly higher in aged PD patients treated by DA compared to those not treated by DA. Our study argues against the initial concepts that ICD incidence would increase with male gender, or higher motor deficits (9, 23).

It has been proposed that LEDD plays a role as a risk factor, which is not supported by our data. In our cohort, the total LEDD contains a substantially higher part of levodopa than of DA. However, in contrast to DA, levodopa does not preferentially stimulate the D3- receptor imputed in generation of ICD symptoms by its impact on cognitive and emotional functions (13). In addition, amantadine, prescribed in 17% of the patients in this cohort, did not show any protective effect against ICD occurrence (24, 25).

There has also been interest in a potential genetic predisposition for ICD in PD. In one study, the dopamine D3 receptor Ser9Gly variant has been linked to higher prevalence of ICD (26). Two variants of the opioid receptor OPRM1 (rs17999 and rs702764) have been associated with decreased odds of ICDs (27, 28). Mutations of the PINK1 and Parkin have been identified as risk factors for ICD (29, 30). All these results await confirmation in independent, larger cohorts.

In the longitudinal analysis, we observed a sharp increase of ICD frequency in DA+ between baseline and V3. We have no data on DA treatment duration and DA dosage before study

entry, so we cannot explicitly dissect if this increase is a time or a dosage effect, reflecting DA accumulation over the years. The latter seems more probable although there may exist an individually variable “tipping point” in terms of postsynaptic dopaminergic hypersensitization (13).

It is appealing to compare our data with other longitudinal studies from Europe, although most of them had a cross-sectional design and were conducted in tertiary care centers. However, studies with a longitudinal follow-up design remain rare. The DIGPD study (France) (5) and the ICARUS study (Italy) (9) are both large, multicenteric cohorts. The DIGPD study (5) included 411 patients (average follow-up 3.3 years); an increase of ICD from 19.7% at baseline to 32.8% after 5 years was reported. With 1,069 subjects included, the ICARUS study (9) reported an ICD prevalence of 26.8% after a 2 year follow-up.

In the U.S., the Prospective Cohort Study of Impulse Control Disorders in Parkinson’s disease (11) longitudinally screened 164 subjects for ICD over 4 years. 39.1% of subjects with DA treatment developed ICD after an average of 21 months. In comparison to these studies, the frequency of ICD at baseline and after 2 years in our study is rather low. This could be due to a more cautious use of DA by the clinicians, based on their acquired knowledge of risky ICD behavior and, in particular, to the more restrictive definition of ICD in our study. However, the lower frequency in the present study probably better reflects numbers expected in the general PD population, but at the same alerts the clinician of increasing frequency of ICD over time.

Several strengths of this study have to be outlined. First, the recruitment of PD patients without any limitations imposed by age or comorbidities allowed a broader appreciation of ICD in the general PD population than in three other studies (5, 9, 11). With a mean age of 65 years, PD patients in our study are also substantially older than those studies (5, 9, 11) (mean age 58,

59 and 62 years, respectively). Second, the inclusive Luxembourg Parkinson's study (15) design also circumvented the preferential recruitment of patients in need of advanced treatment. Third, the physicians in the present observational study were not prescribing nor interfering with treatment. Finally, we were able to follow a large and unselected subgroup of patients longitudinally over three visits, as rarely done before and not at this scale.

Our study has several limitations: first, comparably to other studies (5, 11), ICD occurrence was not confirmed by a second test and defined by MDS-UPDRS part I item 1.6.

In particular, we did not *systematically* use the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease (QUIP) (31), as it is subject to false positive findings. Due to antidepressant use (12), it can produce up to 40% false positive results due to an over-identification or an experience of subsyndromal symptoms (32). Second, we have no reliable data on the medication used before study entry. Finally, our dataset did not allow comparing different DA release forms as lower ICD frequencies have been reported with transdermal DA treatment (33).

In conclusion, our study shows that in PD patients there is a strong association between ICD occurrence and DA treatment. It is independent from gender and age at study entry. Our study cannot robustly show if there is a gender impact on the ICD subtype.

ICD frequency substantially increases over time. Preliminary results from visits 4 and 5 similarly show a trend for ascending ICD frequency over time, but the data obtained so far are insufficient for valid statistical interpretation.

Future research has to identify the type of DA application at highest risk for ICD (34). Analyzing cognitive, affective and motivational correlates or initial PD manifestations could be of interest as well (35). Possibly, the most promising path will be the identification of distinct genotypes that increase the risk for ICD (29, 30). Physicians prescribing DA treatment have to be attentive to the risk of these side effects in *any* PD patient, independent from disease duration and age. They should regularly re-interview PD patients on ICD occurrence, as early ICD absence does not preclude later manifestation.

## DATA AVAILABILITY STATEMENT

Requests to access the datasets should be directed to the coordinator of the NCER-PD research programme, email: rejko.krueger@uni.lu.

## ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the National Ethics Board (CNER Ref: 201407/13) and the National Data Protection Committee (CNPD Ref: 446/2017). The patients/participants provided their written informed consent to participate in this study.

## AUTHOR CONTRIBUTIONS

SB and ND: conception of research project. ND: organization of research project. SB, CP, and GH: execution of research project. SB and RK: supervision of research project. MV: design of statistical analysis. CP and MV: execution of statistical analysis. MV and ND: review and critique of statistical analysis. SB, CP, and ND: writing of the first draft of manuscript preparation. CP, MV, GH, RK, and ND: review and critique of manuscript preparation. All authors contributed to the article and approved the submitted version.

## FUNDING

ND has received research support by the Fonds National de Recherche (FNR/06/04/05), the Fondation Think, Rotary Luxembourg and Rotary International and personal or traveling fees from Alformec (Luxembourg), Bio Expert Nieder-Olm and Klinikum Koblenz (both Germany). RK has received research grants from Fonds National de Recherche de Luxembourg (FNR) as Coordinator of the National Centre for Excellence in Research on Parkinson's disease (NCER-PD) and within the PEARL Excellence Programme [FNR/P13/6682797/Krüger], and the following projects MiRisk [C17/BM/11676395], MotaSYN [12719684], MAMaSyn. Work of RK was supported by the German Research Council (DFG; KR2119/8-1), the Michael J. Fox Foundation, the European Union's Horizon 2020 research and innovation program (WIDESPREAD; CENTRE-PD; grant agreement no. 692320).

## ACKNOWLEDGMENTS

We acknowledge the joint effort of the National Centre of Excellence in Research on Parkinson's Disease (NCER-PD) consortium members generally contributing to the Luxembourg Parkinson's Study as listed below:

Geeta Acharya, Gloria Aguayo, Myriam Alexandre, Dominic Allen, Wim Ammerlann, Maike Aurich, Federico Baldini, Rudi Balling, Peter Banda, Katy Beaumont, Regina Becker, Camille Bellora, Daniela Berg, Fay Betsou, Sylvia Binck, Alexandre Bisdorff, Dheeraj Bobbili, Kathrin Brockmann, Jessica Calmes, Lorieza Castillo, Nico Diederich, Rene Dondelinger, Daniela Esteves, Jean-Yves Ferrand, Ronan Fleming, Manon Gantenbein, Thomas Gasser, Piotr Gawron, Lars Geffers, Virginie Giarmana, Enrico Glaab, Clarissa Gomes, Nikolai Goncharenko, Jérôme Graas, Mariela Graziano, Valentin Groues, Anne Grünwald, Wei Gu, Gaël Hammot, Anne-Marie Hanff, Linda Hansen, Maxime Hansen, Hulda Haraldsdóttir, Laurent Heirendt, Estelle Henry, Sylvia Herbrink, Johannes Hertel, Sascha Herzinger, Michael Heymann, Karsten Hiller, Geraldine Hipp, Michele Hu, Laetitia Huiart, Alexander Hundt, Nadine Jacoby, Jacek Jarosław, Yohan Jaroz, Pierre Kolber, Rejko Krüger, Joachim Kutzera, Pauline Lambert, Zied Landoulsi, Catherine Larue, Roseline Lentz, Inga Liepelt, Robert Liszka, Laura Longhino, Victoria Lorentz, Paula Cristina Lupu, Clare Mackay, Walter Maetzler, Katrin Marcus, Guilherme Marques, Jan Martens, Piotr Matyjaszczyk, Patrick May, Françoise Meisch, Myriam

Menster, Maura Minelli, Michel Mittelbronn, Brit Mollenhauer, Kathleen Mommaerts, Carlos Moreno, Friedrich Mühlischlegel, Romain Nati, Ulf Nehrbass, Sarah Nickels, Beatrice Nicolai, Jean-Paul Nicolay, Alberto Noronha, Wolfgang Oertel, Marek Ostaszewski, Sinthuja Pachchek, Claire Pauly, Lukas Pavelka, Magali Perquin, Dorothea Reiter, Isabel Rosety, Kirsten Rump, Estelle Sandt, Venkata Satagopam, Marc Schlessler, Margaux Schmitt, Sabine Schmitz, Susanne Schmitz, Reinhard Schneider, Jens Schwamborn, Alexandra Schweicher, Kate Sokolowska,

Lara Stute, Ines Thiele, Cyrille Thinnes, Christophe Trefois, Jean-Pierre Trezzi, Johanna Trouet, Michel Vaillant, Daniel Vasco, Maharshi Vyas, Richard Wade-Martins, and Paul Wilmes.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fneur.2020.578924/full#supplementary-material>

## REFERENCES

- World Health Organization. *The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines*. Geneva (1992). p. 211.
- Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. *Arch Neurol.* (2007) 64:1089–96. doi: 10.1001/archneur.64.8.1089
- Grant JE, Murad A, Fineberg NA, Fontenelle LF, Matsunaga H, Janardhan Reddy YC, et al. Impulse control disorders and “behavioural addictions” in the ICD-11. *World Psychiatry.* (2014) 13:125–7. doi: 10.1002/wps.20115
- Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson’s disease. *Mov Disord.* (2009) 24:1561–70. doi: 10.1002/mds.22505
- Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Franck Durif F, Derkinderen P, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. *Neurology.* (2018) 91:e189–201. doi: 10.1212/WNL.0000000000005816
- Cilia R, Siri C, Canesi M, et al. Dopamine dysregulation syndrome in Parkinson’s disease: from clinical and neuropsychological characterisation to management and long-term outcome. *J Neurol, Neurosurg Psych.* (2014) 85:311–8. doi: 10.1136/jnnp-2012-303988
- Warren N, O’Gorman C, Lehn A, Siskind D. Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases. *J Neurol Neurosurg Psychiatry.* (2017) 88:1060–4. doi: 10.1136/jnnp-2017-315985
- Smith KM, Xie SX, Weintraub D. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. *J Neurol Neurosurg Psychiatry.* (2016) 87:864–70. doi: 10.1136/jnnp-2015-311827
- Antonini A, Barone P, Bonuccelli U, Annoni K, Asgharnejad M, Stanzione M, et al. ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease. *J Neurol Neurosurg Psychiatry.* (2017) 88:317–24. doi: 10.1136/jnnp-2016-315277
- Baig F, Kelly MJ, Lawton MA, Ruffmann C, Rolinski M, Klein JC, et al. Impulse control disorders in Parkinson disease and RBD: a longitudinal study of severity. *Neurology.* (2019) 93:e675–87. doi: 10.1212/WNL.0000000000007942
- Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson’s disease. *Mov Disord.* (2013) 28:327–33. doi: 10.1002/mds.25291
- Carbunaru S, Eisinger RS, Ramirez-Zamora A, Bassan D, Cervantes-Arriaga A, Rodriguez-Violante M, et al. Impulse control disorders in Parkinson’s: sleep disorders and nondopaminergic associations. *Brain Behav.* (2018) 8:e00904. doi: 10.1002/brb3.904
- Seeman P. Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. *Synapse.* (2015) 69:183–9. doi: 10.1002/syn.21805
- Gatto EM, Aldinio V. Impulse control disorders in Parkinson’s disease. A brief and comprehensive review. *Front Neurol.* (2019) 10:e351. doi: 10.3389/fneur.2019.00351
- Hipp G, Vaillant M, Diederich NJ, Roomp K, Satagopam VP, Banda P, et al. The luxembourg Parkinson’s study: a comprehensive approach for stratification and early diagnosis. *Front Aging Neurosci.* (2018) 10:e326. doi: 10.3389/fnagi.2018.00326
- De Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. *Lancet Neurol.* (2006) 5:525–35. doi: 10.1016/S1474-4422(06)70471-9
- Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry.* (1992) 55:181–4. doi: 10.1136/jnnp.55.3.181
- Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for cognitive impairment. *J Am Geriatr Soc.* (2005) 53:695–9. doi: 10.1111/j.1532-5415.2005.53221.x
- Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. *Mov Disord.* (2010) 25:2649–53. doi: 10.1002/mds.23429
- Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord.* (2008) 23:2129–70. doi: 10.1002/mds.22340
- Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement disorder society task force on rating scales for Parkinson’s Disease. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. *Mov Disord.* (2004) 19:1020–8. doi: 10.1002/mds.20213
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* (2009) 42:377–81. doi: 10.1016/j.jbi.2008.08.010
- Waghalkar M, Gupta V, Jukkarwala A. *Impulse Control Disorder in the Patients of Parkinson’s Disease: Various Correlations [abstract]*. International Parkinson and Movement Disorder Society (2020). Available online at: <https://www.mdsabstracts.org/abstract/impulse-control-disorder-in-the-patients-of-parkinsons-disease-various-correlations/> (accessed September 28, 2020).
- Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofri M. Pathological gambling in parkinson disease is reduced by amantadine. *Ann Neurol.* (2010) 68:400–4. doi: 10.1002/ana.22029
- Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. *Ann Neurol.* (2010) 68:963–8. doi: 10.1002/ana.22164
- Krishnamoorthy S, Rajan R, Banerjee M, Kumar H, Sarma G, Krishnan S, et al. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson’s disease patients. *Parkinsonism Relat Disord.* (2016) 30:13–7. doi: 10.1016/j.parkreldis.2016.06.005
- Cormier-Dequaire F, Bekadar S, Anheim M, Lebbah S, Pelissolo A, Krack P, et al. Suggestive association between OPRM1 and impulse control disorders in Parkinson’s disease. *Mov Disord.* (2018) 33:1878–86. doi: 10.1002/mds.27519
- Erga AH, Dalen I, Ushakova A, Chung J, Tzoulis C, Tysnes OB, et al. Dopaminergic and opioid pathways associated with impulse control disorders in Parkinson’s disease. *Front Neurol.* (2018) 9:109. doi: 10.3389/fneur.2018.00109
- Aasly JO. Long-term outcomes of genetic parkinson’s disease. *J Mov Disorder.* (2020) 13:81–96. doi: 10.14802/jmd.19080

30. Morgante F, Fasano A, Ginevrino M, Petrucci S, Ricciardi L, Bove F, et al. Impulsive-compulsive behaviors in parkin-associated Parkinson disease. *Neurology*. (2016) 87:1436–41. doi: 10.1212/WNL.0000000000003177
31. Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A. Questionnaire for impulsive-compulsive disorders in Parkinson's Disease-Rating Scale. *Mov Disord*. (2012) 27:242–7. doi: 10.1002/mds.24023
32. Evans AH, Okai D, Weintraub D, Lim S-H, O'Sullivan SS, Voon V, et al. Scales to assess impulsive and compulsive behaviors in Parkinson's disease: critique and recommendations. *Mov Disord*. (2019) 34:791–8. doi: 10.1002/mds.27689
33. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. *Mov Disord*. (2007) 22:1757–63. doi: 10.1002/mds.21611
34. Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B, et al. A European Multicentre Survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. *Eur J Neurol*. (2016) 23:1255–61. doi: 10.1111/ene.13034
35. Martini A, Dal Lago D, Edelstyn NMJ, Grange JA, Tamburin S. Impulse control disorder in parkinson's disease: a meta-analysis of cognitive, affective, and motivational correlates. *Front Neurol*. (2018) 9:e654. doi: 10.3389/fneur.2018.00654

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Binck, Pauly, Vaillant, Hipp, Gantenbein, Krueger and Diederich. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.